Immix Biopharma, Inc.
IMMX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $11 | $9 | $4 | $0 |
| G&A Expenses | $11 | $7 | $4 | $1 |
| SG&A Expenses | $11 | $7 | $4 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $23 | $16 | $8 | $1 |
| Operating Income | -$23 | -$16 | -$8 | -$1 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | -$0 | -$23 |
| Pre-Tax Income | -$22 | -$16 | -$8 | -$24 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$22 | -$15 | -$8 | -$24 |
| % Margin | – | – | – | – |
| EPS | -0.76 | -0.89 | -0.59 | -6.64 |
| % Growth | 14.6% | -50.8% | 91.1% | – |
| EPS Diluted | -0.76 | -0.89 | -0.59 | -6.64 |
| Weighted Avg Shares Out | 28 | 17 | 14 | 4 |
| Weighted Avg Shares Out Dil | 28 | 17 | 14 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$23 | -$16 | -$8 | -$24 |
| % Margin | – | – | – | – |